Skip to main content
SpringerLink
Log in

A Semi-mechanistic Modeling Strategy for Characterization of Regional Absorption Properties and Prospective Prediction of Plasma Concentrations Following Administration of New Modified Release Formulations

  • Research Paper
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

ABSTRACT

Purpose

To outline and test a new modeling approach for prospective predictions of absorption from newly developed modified release formulations based on in vivo studies of gastro intestinal (GI) transit, drug release and regional absorption for the investigational drug AZD0837.

Methods

This work was a natural extension to the companion article “A semi-mechanistic model to link in vitro and in vivo drug release for modified release formulations”. The drug release model governed the amount of substance released in distinct GI regions over time. GI distribution of released drug substance, region specific rate and extent of absorption and the influence of food intake were estimated. The model was informed by magnetic marker monitoring data and data from an intubation study with local administration in colon.

Results

Distinctly different absorption properties were characterized for different GI regions. Bioavailability over the gut-wall was estimated to be high in duodenum (70%) compared to the small intestine (25%). Colon was primarily characterized by a very slow rate of absorption.

Conclusions

The established model was largely successful in predicting plasma concentration following administration of three newly developed formulations for which no clinical data had been applied during model building.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

REFERENCES

  1. Casey DL, Beihn RM, Digenis GA, Shambhu MB. Method for monitoring hard gelatin capsule disintegration times in humans using external scintigraphy. J Pharm Sci. 1976;65(9):1412–3.

    Article  PubMed  CAS  Google Scholar 

  2. Digenis GA, Sandefer EP, Page RC, Doll WJ. Gamma scintigraphy: An evolving technology in pharmaceutical formulation development - Part 1. Pharm Sci Technol Today. 1998;1(3):100–7.

    Article  Google Scholar 

  3. Digenis GA, Sandefer EP, Page RC, Doll WJ. Gamma scintigraphy: An evolving technology in pharmaceutical formulation development - Part 2. Pharm Sci Technol Today. 1998;1(4):160–5.

    Article  CAS  Google Scholar 

  4. Weitschies W, Blume H, Mönnikes H. Magnetic marker monitoring: High resolution real-time tracking of oral solid dosage forms in the gastrointestinal tract. Eur J Pharm Biopharm. 2009;74(1):93–101.

    Article  PubMed  Google Scholar 

  5. Weitschies W, Kosch O, Mönnikes H, Trahms L. Magnetic Marker Monitoring: An application of biomagnetic measurement instrumentation and principles for the determination of the gastrointestinal behavior of magnetically marked solid dosage forms. Adv Drug Deliv Rev. 2005;57(8):1210–22.

    Article  PubMed  CAS  Google Scholar 

  6. Bergstrand M, Söderlind E, Weitschies W, Karlsson MO. Mechanistic modeling of a magnetic marker monitoring study linking gastrointestinal tablet transit, in vivo drug release, and pharmacokinetics. Clin Pharmacol Ther. 2009 Jul;86(1):77–83.

    Article  CAS  Google Scholar 

  7. Sutton SC. The use of gastrointestinal intubation studies for controlled release development. Br J Clin Pharmacol. 2009;68(3):342–54.

    Article  PubMed  CAS  Google Scholar 

  8. Nyberg L, Mansson W, Abrahamsson B, Seidegard J, Borga O. A convenient method for local drug administration at predefined sites in the entire gastrointestinal tract: experiences from 13 phase I studies. Eur J Pharm Sci. 2007 Apr;30(5):432–40.

    Article  CAS  Google Scholar 

  9. Olsson SB, Rasmussen LH, Tveit A, Jensen E, Wessman P, Panfilov S, et al. Safety and tolerability of an immediate-release formulation of the oral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Thromb Haemost. 2010;103(3):604–12.

    Article  PubMed  CAS  Google Scholar 

  10. Johansson S, Cullberg M, Eriksson UG, Elg M, Dunér K, Jensen E, et al. Single-dose pharmacokinetics, pharmacodynamics and safety of AZD0837, a novel oral direct thrombin inhibitor, in young healthy male subjects. Int J Clin Pharmacol Ther. 2011;49(4):258–67.

    PubMed  CAS  Google Scholar 

  11. Lip GYH, Rasmussen LH, Olsson SB, Jensen EC, Persson AL, Eriksson U, et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: A randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. Eur Heart J. 2009;30(23):2897–907.

    Article  PubMed  CAS  Google Scholar 

  12. Bergstrand M, Söderlind E, Eriksson UG, Weitschies W, Karlsson MO. A mechanistic model to link in vitro and in vivo drug release for modified release formulations. [unpublished companion manuscript].

  13. Beal SL, Sheiner LB, Boeckmann AJ. NONMEM User’s Guides. Ellicot City: MD: Icon Development Solutions; 1989–2006.

  14. Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)–a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004 Aug;75(2):85–94.

    Article  Google Scholar 

  15. Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit–a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005 Sep;79(3):241–57.

    Article  Google Scholar 

  16. Jonsson EN, Karlsson MO. Xpose–an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999 Jan;58(1):51–64.

    Article  CAS  Google Scholar 

  17. Harling K, Ueckert S, Hooker AC, Jonsson EN, Karlsson MO. Xpose and Perl speaks NONMEM (PsN). PAGE 19 (2010) Abstr 1842 [wwwpage-meetingorg/?abstract=1842].

  18. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2009 [2009-12-30]; Available from: http://www.R-project.org.

  19. Gordi T, Xie R, Huong NV, Huong DX, Karlsson MO, Ashton M. A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction. Br J Clin Pharmacol. 2005 Feb;59(2):189–98.

    Article  CAS  Google Scholar 

  20. Gordi T, Xie R, Huong NV, Huong DX, Karlsson MO, Ashton M. A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction. Br J Clin Pharmacol. 2005;59(2):189–98.

    Article  PubMed  CAS  Google Scholar 

  21. Magnusson MO, Dahl ML, Cederberg J, Karlsson MO, Sandström R. Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin. Clin Pharmacol Ther. 2008;84(1):52–62.

    Article  PubMed  CAS  Google Scholar 

  22. Holford NH. A size standard for pharmacokinetics. Clin Pharmacokinet. 1996 May;30(5):329–32.

    Article  CAS  Google Scholar 

  23. Weitschies W, Cardini D, Karaus M, Trahms L, Semmler W. Magnetic marker monitoring of esophageal, gastric and duodenal transit of non-disintegrating capsules. Pharmazie. 1999 Jun;54(6):426–30.

    CAS  Google Scholar 

  24. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models. AAPS J. 2011 in press.

  25. Thelen K, Dressman JB. Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol. 2009;61(5):541–58.

    Article  PubMed  CAS  Google Scholar 

  26. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther. 1997 Dec;283(3):1552–62.

    CAS  Google Scholar 

  27. Zeldin DC, Foley J, Goldsworthy SM, Cook ME, Boyle JE, Ma J, et al. CYP2J subfamily cytochrome P450s in the gastrointestinal tract: Expression, localization, and potential functional significance. Mol Pharmacol. 1997;51(6):931–43.

    PubMed  CAS  Google Scholar 

  28. Jantratid E, De Maio V, Ronda E, Mattavelli V, Vertzoni M, Dressman JB. Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form. Eur J Pharm Sci. 2009;37(3–4):434–41.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Biosciences, Uppsala University, P.O. Box 591, SE-751 24, Uppsala, Sweden

    Martin Bergstrand & Mats O Karlsson

  2. Pharmaceutical Development, AstraZeneca R&D, Mölndal, Sweden

    Erik Söderlind

  3. AstraZeneca R&D, Mölndal, Sweden

    Ulf G Eriksson

  4. Institute of Pharmacy, University of Greifswald, Greifswald, Germany

    Werner Weitschies

Authors
  1. Martin Bergstrand
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erik Söderlind
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ulf G Eriksson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Werner Weitschies
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mats O Karlsson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Bergstrand.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bergstrand, M., Söderlind, E., Eriksson, U.G. et al. A Semi-mechanistic Modeling Strategy for Characterization of Regional Absorption Properties and Prospective Prediction of Plasma Concentrations Following Administration of New Modified Release Formulations. Pharm Res 29, 574–584 (2012). https://doi.org/10.1007/s11095-011-0595-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11095-011-0595-2

KEY WORDS

Search

Navigation